Want to see KR:006280 full AI Analyst Report?
GC Biopharma Corp. (006280) Income Statement
GC Biopharma Corp. Income Statement
Last quarter (Q2 2026), GC Biopharma Corp.'s total revenue was $421.20B, a decrease of 15.80% from the same quarter last year. In Q2, GC Biopharma Corp.'s net income was $1.98B. See GC Biopharma Corp.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 1.99T | $ 1.68T | $ 1.63T | $ 1.71T | $ 1.54T | |
| $ 536.00B | $ 481.93B | $ 484.63B | $ 581.80B | $ 520.59B | |
| $ 468.19B | $ 449.82B | $ 450.20B | $ 500.54B | $ 446.86B | |
| Depreciation and Amortization | $ 87.66B | $ 81.03B | $ 75.90B | $ 65.10B | $ 55.90B |
| $ 155.46B | $ 80.36B | $ 109.81B | $ 187.32B | $ 159.43B | |
| $ 67.81B | $ 32.11B | $ 34.44B | $ 81.26B | $ 73.66B | |
| $ -104.48B | $ -73.22B | $ -61.57B | $ 4.46B | $ 98.90B | |
| $ -35.33B | $ -41.11B | $ -27.13B | $ 85.73B | $ 172.56B | |
| $ -4.67B | $ -26.28B | $ -26.63B | $ 65.45B | $ 123.21B | |
| Per Share Metrics | |||||
| Basic EPS | $ -409.51 | $ -2302.62 | $ -2333.42 | $ 5734.87 | $ 10795.00 |
| Diluted EPS | $ -409.51 | $ -2302.62 | $ -2333.42 | $ 5734.87 | $ 10795.00 |
| Weighted Average Shares Outstanding | 11.41M | 11.41M | 11.41M | 11.41M | 11.41M |
| Weighted Average Shares Outstanding (Diluted) | 11.41M | 11.41M | 11.41M | 11.41M | 11.41M |
Currency in KRW
